Outcome was analyzed based on two clinical endpoints; PSA progression after treatment with ADT or prostate cancer-specific death, with 22 patients having PSA progression and 11 patients dying from prostate cancer during the study period. This evidence concerns the gene KLK3 and prostate cancer.